A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1072

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG: insulin glargine
DRUG: metformin
DRUG: taspoglutide
DRUG: taspoglutide

Sponsor

Hoffmann-La Roche